Shares of Haemonetics Corp. (NYSE:HAE) have been assigned an average rating of “Hold” from the twelve ratings firms that are presently covering the stock. Three investment analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $33.17.

A number of equities research analysts have recently weighed in on HAE shares. CJS Securities lowered shares of Haemonetics Corp. from a “market outperform” rating to a “market perform” rating and set a $35.00 target price on the stock. in a research note on Tuesday, September 20th. Jefferies Group lifted their price target on shares of Haemonetics Corp. from $32.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, August 2nd. Benchmark Co. lifted their price target on shares of Haemonetics Corp. from $28.00 to $32.00 and gave the company a “hold” rating in a research report on Tuesday, August 2nd. Barrington Research cut shares of Haemonetics Corp. from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 3rd. Finally, Zacks Investment Research raised shares of Haemonetics Corp. from a “strong sell” rating to a “hold” rating in a research report on Monday, July 4th.

In related news, CEO Christopher Simon acquired 60,000 shares of the firm’s stock in a transaction dated Thursday, August 4th. The stock was purchased at an average cost of $35.00 per share, with a total value of $2,100,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ronald Merriman sold 4,337 shares of the business’s stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $35.14, for a total transaction of $152,402.18. Following the transaction, the director now directly owns 22,088 shares of the company’s stock, valued at $776,172.32. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its position in Haemonetics Corp. by 125.7% in the first quarter. BlackRock Inc. now owns 3,501 shares of the company’s stock valued at $122,000 after buying an additional 1,950 shares during the last quarter. Tower Research Capital LLC TRC bought a new position in Haemonetics Corp. during the second quarter valued at $133,000. Invictus RG boosted its position in Haemonetics Corp. by 20.1% in the first quarter. Invictus RG now owns 4,074 shares of the company’s stock valued at $143,000 after buying an additional 681 shares during the last quarter. PineBridge Investments L.P. boosted its position in Haemonetics Corp. by 4.2% in the second quarter. PineBridge Investments L.P. now owns 6,473 shares of the company’s stock valued at $187,000 after buying an additional 261 shares during the last quarter. Finally, Teacher Retirement System of Texas boosted its position in Haemonetics Corp. by 13.9% in the second quarter. Teacher Retirement System of Texas now owns 7,081 shares of the company’s stock valued at $205,000 after buying an additional 865 shares during the last quarter. 98.60% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Corp. (NYSE:HAE) traded up 0.49% on Tuesday, hitting $34.64. 275,090 shares of the stock were exchanged. The stock’s market cap is $1.78 billion. Haemonetics Corp. has a 12 month low of $25.98 and a 12 month high of $38.06. The company has a 50-day moving average of $36.71 and a 200-day moving average of $32.58.

Haemonetics Corp. (NYSE:HAE) last announced its earnings results on Monday, August 1st. The company reported $0.25 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by $0.03. The company had revenue of $210 million for the quarter, compared to the consensus estimate of $205.41 million. Haemonetics Corp. had a negative net margin of 7.25% and a positive return on equity of 10.75%. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.35 EPS. On average, equities analysts predict that Haemonetics Corp. will post $1.44 EPS for the current year.

About Haemonetics Corp.

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

5 Day Chart for NYSE:HAE

Receive News & Stock Ratings for Haemonetics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corp. and related stocks with our FREE daily email newsletter.